Zhengye Biotechnology Holding Ltd
ZYBT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001975641
No open-market purchases or sales by Zhengye Biotechnology Holding Ltd insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $68.1K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Zhengye Biotechnology Holding Ltd as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 8
- 0 vs. Q1 2026
- Shares held
- 100.3K
- −20.8K (−17.2%) vs. Q1 2026
- Total value
- $68.1K
- −$44.9K (−39.8%) vs. Q1 2026
- New holders
- 1
- 1 more added
- Sold out
- 1
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZYBT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $68.1K |
| Q1 2026 | 8 | $113.0K |
| Q4 2025 | 11 | $264.8K |
| Q3 2025 | 10 | $415.9K |
| Q2 2025 | 9 | $2.51M |
| Q1 2025 | 3 | $7.19K |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Zhengye Biotechnology Holding Ltd; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| XTX Topco Ltd | 48,865 | $33.1K | 0.00% | +4,719+10.7% | Added |
| Geode Capital Management, LLC | 29,068 | $19.7K | 0.00% | 00.0% | Unchanged |
| Winton Group Ltd | 12,730 | $8.62K | 0.00% | −20,659−61.9% | Reduced |
| UBS Group AG | 7,992 | $5.41K | 0.00% | −44−0.5% | Reduced |
| Royal Bank of Canada | 1,230 | $1.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 248 | $168 | 0.00% | −13−5.0% | Reduced |
| JPMorgan Chase & Co | 134 | $93 | 0.00% | +134 | New |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −4,912−100.0% | Sold out |